Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice

Francesco Salerno, Massimo Cazzaniga, Manuela Merli, Giancarlo Spinzi, Simone Saibeni, Andrea Salmi, Stefano Fagiuoli, Antonio Spadaccini, Elisa Trotta, Giacomo Laffi, Maurizio Koch, Oliviero Riggio, Sergio Boccia, Martina Felder, Simona Balzani, Savino Bruno, Paolo Angeli

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background & Aims: Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin. Aim of this prospective cohort study was to investigate the prevalence of HRS, diagnostic criteria, treatment and 3-month outcome in the daily-clinical-practice. Methods: Two-hundred-fifty-three patients with cirrhosis and renal failure consecutively admitted to 21 Italian hospitals were recruited. Results: The prevalence of HRS was 45.8% (30% type-1 and 15.8% type-2). In 36% of cases HRS was presumed because not all diagnostic criteria could be fulfilled. In 8% of cases HRS was superimposed on an organic nephropathy. Patients with HRS type-1 were younger and showed higher leukocyte count, higher respiratory rates, and worse liver function scores. Sixty-four patients with HRS type-1 received vasoconstrictors (40 terlipressin and 24 midodrine/octreotide). A complete response was obtained in 19 cases (30%) and a partial response in 13 (20%). Age was the only independent predictor of response (p = 0.033). Three-month survival of patients with HRS type-1 was 19.7%. Survival was better in patients who responded to therapy. Age (p = 0.017), bilirubin (p = 0.012), and creatinine increase after diagnostic volume expansion (p = 0.02) independently predicted death. The mortality rate was 97% among patients with at least two negative predictors. Conclusions: The diagnostic criteria of HRS in our daily-clinical-practice could not be completely fulfilled in one third of cases. The treatment with vasoconstrictors and albumin was widely implemented. Mortality was strongly predicted by simple baseline variables.

Original languageEnglish
Pages (from-to)1241-1248
Number of pages8
JournalJournal of Hepatology
Volume55
Issue number6
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Hepatorenal Syndrome
Survival
Vasoconstrictor Agents
Therapeutics
Ascites
Albumins
Fibrosis
Midodrine
Surveys and Questionnaires
Octreotide
Mortality
Respiratory Rate
Leukocyte Count
Bilirubin
Renal Insufficiency
Creatinine
Cohort Studies
Prospective Studies

Keywords

  • Ascites
  • Kidney
  • Midodrine
  • Portal hypertension
  • Terlipressin

ASJC Scopus subject areas

  • Hepatology

Cite this

Salerno, F., Cazzaniga, M., Merli, M., Spinzi, G., Saibeni, S., Salmi, A., ... Angeli, P. (2011). Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. Journal of Hepatology, 55(6), 1241-1248. https://doi.org/10.1016/j.jhep.2011.03.012

Diagnosis, treatment and survival of patients with hepatorenal syndrome : A survey on daily medical practice. / Salerno, Francesco; Cazzaniga, Massimo; Merli, Manuela; Spinzi, Giancarlo; Saibeni, Simone; Salmi, Andrea; Fagiuoli, Stefano; Spadaccini, Antonio; Trotta, Elisa; Laffi, Giacomo; Koch, Maurizio; Riggio, Oliviero; Boccia, Sergio; Felder, Martina; Balzani, Simona; Bruno, Savino; Angeli, Paolo.

In: Journal of Hepatology, Vol. 55, No. 6, 12.2011, p. 1241-1248.

Research output: Contribution to journalArticle

Salerno, F, Cazzaniga, M, Merli, M, Spinzi, G, Saibeni, S, Salmi, A, Fagiuoli, S, Spadaccini, A, Trotta, E, Laffi, G, Koch, M, Riggio, O, Boccia, S, Felder, M, Balzani, S, Bruno, S & Angeli, P 2011, 'Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice', Journal of Hepatology, vol. 55, no. 6, pp. 1241-1248. https://doi.org/10.1016/j.jhep.2011.03.012
Salerno, Francesco ; Cazzaniga, Massimo ; Merli, Manuela ; Spinzi, Giancarlo ; Saibeni, Simone ; Salmi, Andrea ; Fagiuoli, Stefano ; Spadaccini, Antonio ; Trotta, Elisa ; Laffi, Giacomo ; Koch, Maurizio ; Riggio, Oliviero ; Boccia, Sergio ; Felder, Martina ; Balzani, Simona ; Bruno, Savino ; Angeli, Paolo. / Diagnosis, treatment and survival of patients with hepatorenal syndrome : A survey on daily medical practice. In: Journal of Hepatology. 2011 ; Vol. 55, No. 6. pp. 1241-1248.
@article{d8e788bf0f324176b0dc448929bacfbf,
title = "Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice",
abstract = "Background & Aims: Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin. Aim of this prospective cohort study was to investigate the prevalence of HRS, diagnostic criteria, treatment and 3-month outcome in the daily-clinical-practice. Methods: Two-hundred-fifty-three patients with cirrhosis and renal failure consecutively admitted to 21 Italian hospitals were recruited. Results: The prevalence of HRS was 45.8{\%} (30{\%} type-1 and 15.8{\%} type-2). In 36{\%} of cases HRS was presumed because not all diagnostic criteria could be fulfilled. In 8{\%} of cases HRS was superimposed on an organic nephropathy. Patients with HRS type-1 were younger and showed higher leukocyte count, higher respiratory rates, and worse liver function scores. Sixty-four patients with HRS type-1 received vasoconstrictors (40 terlipressin and 24 midodrine/octreotide). A complete response was obtained in 19 cases (30{\%}) and a partial response in 13 (20{\%}). Age was the only independent predictor of response (p = 0.033). Three-month survival of patients with HRS type-1 was 19.7{\%}. Survival was better in patients who responded to therapy. Age (p = 0.017), bilirubin (p = 0.012), and creatinine increase after diagnostic volume expansion (p = 0.02) independently predicted death. The mortality rate was 97{\%} among patients with at least two negative predictors. Conclusions: The diagnostic criteria of HRS in our daily-clinical-practice could not be completely fulfilled in one third of cases. The treatment with vasoconstrictors and albumin was widely implemented. Mortality was strongly predicted by simple baseline variables.",
keywords = "Ascites, Kidney, Midodrine, Portal hypertension, Terlipressin",
author = "Francesco Salerno and Massimo Cazzaniga and Manuela Merli and Giancarlo Spinzi and Simone Saibeni and Andrea Salmi and Stefano Fagiuoli and Antonio Spadaccini and Elisa Trotta and Giacomo Laffi and Maurizio Koch and Oliviero Riggio and Sergio Boccia and Martina Felder and Simona Balzani and Savino Bruno and Paolo Angeli",
year = "2011",
month = "12",
doi = "10.1016/j.jhep.2011.03.012",
language = "English",
volume = "55",
pages = "1241--1248",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Diagnosis, treatment and survival of patients with hepatorenal syndrome

T2 - A survey on daily medical practice

AU - Salerno, Francesco

AU - Cazzaniga, Massimo

AU - Merli, Manuela

AU - Spinzi, Giancarlo

AU - Saibeni, Simone

AU - Salmi, Andrea

AU - Fagiuoli, Stefano

AU - Spadaccini, Antonio

AU - Trotta, Elisa

AU - Laffi, Giacomo

AU - Koch, Maurizio

AU - Riggio, Oliviero

AU - Boccia, Sergio

AU - Felder, Martina

AU - Balzani, Simona

AU - Bruno, Savino

AU - Angeli, Paolo

PY - 2011/12

Y1 - 2011/12

N2 - Background & Aims: Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin. Aim of this prospective cohort study was to investigate the prevalence of HRS, diagnostic criteria, treatment and 3-month outcome in the daily-clinical-practice. Methods: Two-hundred-fifty-three patients with cirrhosis and renal failure consecutively admitted to 21 Italian hospitals were recruited. Results: The prevalence of HRS was 45.8% (30% type-1 and 15.8% type-2). In 36% of cases HRS was presumed because not all diagnostic criteria could be fulfilled. In 8% of cases HRS was superimposed on an organic nephropathy. Patients with HRS type-1 were younger and showed higher leukocyte count, higher respiratory rates, and worse liver function scores. Sixty-four patients with HRS type-1 received vasoconstrictors (40 terlipressin and 24 midodrine/octreotide). A complete response was obtained in 19 cases (30%) and a partial response in 13 (20%). Age was the only independent predictor of response (p = 0.033). Three-month survival of patients with HRS type-1 was 19.7%. Survival was better in patients who responded to therapy. Age (p = 0.017), bilirubin (p = 0.012), and creatinine increase after diagnostic volume expansion (p = 0.02) independently predicted death. The mortality rate was 97% among patients with at least two negative predictors. Conclusions: The diagnostic criteria of HRS in our daily-clinical-practice could not be completely fulfilled in one third of cases. The treatment with vasoconstrictors and albumin was widely implemented. Mortality was strongly predicted by simple baseline variables.

AB - Background & Aims: Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin. Aim of this prospective cohort study was to investigate the prevalence of HRS, diagnostic criteria, treatment and 3-month outcome in the daily-clinical-practice. Methods: Two-hundred-fifty-three patients with cirrhosis and renal failure consecutively admitted to 21 Italian hospitals were recruited. Results: The prevalence of HRS was 45.8% (30% type-1 and 15.8% type-2). In 36% of cases HRS was presumed because not all diagnostic criteria could be fulfilled. In 8% of cases HRS was superimposed on an organic nephropathy. Patients with HRS type-1 were younger and showed higher leukocyte count, higher respiratory rates, and worse liver function scores. Sixty-four patients with HRS type-1 received vasoconstrictors (40 terlipressin and 24 midodrine/octreotide). A complete response was obtained in 19 cases (30%) and a partial response in 13 (20%). Age was the only independent predictor of response (p = 0.033). Three-month survival of patients with HRS type-1 was 19.7%. Survival was better in patients who responded to therapy. Age (p = 0.017), bilirubin (p = 0.012), and creatinine increase after diagnostic volume expansion (p = 0.02) independently predicted death. The mortality rate was 97% among patients with at least two negative predictors. Conclusions: The diagnostic criteria of HRS in our daily-clinical-practice could not be completely fulfilled in one third of cases. The treatment with vasoconstrictors and albumin was widely implemented. Mortality was strongly predicted by simple baseline variables.

KW - Ascites

KW - Kidney

KW - Midodrine

KW - Portal hypertension

KW - Terlipressin

UR - http://www.scopus.com/inward/record.url?scp=81355138638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355138638&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.03.012

DO - 10.1016/j.jhep.2011.03.012

M3 - Article

C2 - 21703199

AN - SCOPUS:81355138638

VL - 55

SP - 1241

EP - 1248

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -